MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 130 filers reported holding MERSANA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,426 | -89.9% | 42,068 | -73.8% | 0.00% | -100.0% |
| Q2 2023 | $527,397 | +6013.3% | 160,303 | +7537.1% | 0.00% | – |
| Q1 2023 | $8,627 | +72.5% | 2,099 | +182.9% | 0.00% | – |
| Q3 2022 | $5,000 | -44.4% | 742 | -63.3% | 0.00% | – |
| Q2 2022 | $9,000 | -87.5% | 2,023 | -88.8% | 0.00% | – |
| Q1 2022 | $72,000 | +800.0% | 18,123 | +1269.8% | 0.00% | – |
| Q4 2021 | $8,000 | -77.8% | 1,323 | -65.6% | 0.00% | – |
| Q3 2021 | $36,000 | -75.0% | 3,849 | -56.6% | 0.00% | – |
| Q1 2021 | $144,000 | +34.6% | 8,870 | +121.4% | 0.00% | – |
| Q4 2020 | $107,000 | – | 4,007 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |